<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="oration" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Medical academic journal</journal-id><journal-title-group><journal-title xml:lang="en">Medical academic journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Медицинский академический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1608-4101</issn><issn publication-format="electronic">2687-1378</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">78155</article-id><article-id pub-id-type="doi">10.17816/MAJ78155</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Conference proceedings</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Материалы конференции</subject></subj-group><subj-group subj-group-type="article-type"><subject>Conference Report, Theses of Report</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The role of coinfection with influenza viruses in the pathogenesis of severe infection in patients with COVID-19</article-title><trans-title-group xml:lang="ru"><trans-title>Роль коинфекции вирусами гриппа при тяжелом течении COVID-19</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6649-8150</contrib-id><name-alternatives><name xml:lang="en"><surname>Shvedova</surname><given-names>Tamara N.</given-names></name><name xml:lang="ru"><surname>Шведова</surname><given-names>Тамара Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Head of the Clinical Diagnostic Laboratory</p></bio><bio xml:lang="ru"><p>заведующая клинико-диагностической лабораторией, врач</p></bio><email>toma_nn@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2645-3433</contrib-id><contrib-id contrib-id-type="spin">7630-3067</contrib-id><name-alternatives><name xml:lang="en"><surname>Kopteva</surname><given-names>Olga S.</given-names></name><name xml:lang="ru"><surname>Коптева</surname><given-names>Ольга Сергеевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate student</p></bio><bio xml:lang="ru"><p>аспирант</p></bio><email>olga.s.kopteva@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kudar</surname><given-names>Polina A.</given-names></name><name xml:lang="ru"><surname>Кударь</surname><given-names>Полина Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Student, Department of Virology</p></bio><bio xml:lang="ru"><p>студентка, отдел вирусологии</p></bio><email>polina6226@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5848-6486</contrib-id><name-alternatives><name xml:lang="en"><surname>Lerner</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Лернер</surname><given-names>Анна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Med.), Chief Staff Ofisser for Clinical Laboratory Diagnostics; assistant of the Department of Clinical Laboratory Diagnostics</p></bio><bio xml:lang="ru"><p>канд. мед. наук, главный штатный специалист по клинической лабораторной диагностике; ассистент кафедры клинической лабораторной диагностики</p></bio><email>sever67@bk.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9794-3520</contrib-id><name-alternatives><name xml:lang="en"><surname>Desheva</surname><given-names>Yuliya A.</given-names></name><name xml:lang="ru"><surname>Дешева</surname><given-names>Юлия Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, PhD, DSc (Med.), Associate Professor, Professor of the Department of Fundamental Problems of Medicine and Medical Technologies, Faculty of Dentistry and Medical Technologies; Leading Researcher of the Department of Virology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, доцент, профессор кафедры фундаментальных проблем медицины и медицинских технологий, факультет стоматологии и медицинских технологий; ведущий научный сотрудник отдела вирусологии</p></bio><email>desheva@mail.ru</email><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Vsevolozhsk Clinical Multidisciplinary Hospital</institution></aff><aff><institution xml:lang="ru">Всеволожская клиническая многопрофильная больница</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Experimental Medicine</institution></aff><aff><institution xml:lang="ru">Институт экспериментальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">North-Western State Medical University named after I.I. Mechnikov</institution></aff><aff><institution xml:lang="ru">Северо-Западный государственный медицинский университет им. И.И. Мечникова</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2021-09-01" publication-format="electronic"><day>01</day><month>09</month><year>2021</year></pub-date><pub-date date-type="pub" iso-8601-date="2021-12-06" publication-format="electronic"><day>06</day><month>12</month><year>2021</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>159</fpage><lpage>164</lpage><history><date date-type="received" iso-8601-date="2021-08-16"><day>16</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-09-01"><day>01</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Shvedova T.N., Kopteva O.S., Kudar P.A., Lerner A.A., Desheva Y.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Шведова Т.Н., Коптева О.С., Кударь П.А., Лернер А.А., Дешева Ю.А.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Shvedova T.N., Kopteva O.S., Kudar P.A., Lerner A.A., Desheva Y.A.</copyright-holder><copyright-holder xml:lang="ru">Шведова Т.Н., Коптева О.С., Кударь П.А., Лернер А.А., Дешева Ю.А.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/MAJ/article/view/78155">https://journals.eco-vector.com/MAJ/article/view/78155</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND:</italic></bold> Despite the continuing global spread of the coronavirus infection COVID-19 caused by the SARS-CoV-2 coronavirus, the mechanisms of the pathogenesis of severe infections remain poorly understood. The role of comorbidity with other seasonal viral infections, including influenza, in the pathogenesis of the severe course of COVID-19 remains unclear.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold> The present study used sera left over from ongoing laboratory studies of patients with varying degrees of severity of COVID-19. The study was approved by the Local Ethics Committee of the Federal State Budgetary Scientific Institution “IEM” (protocol 3/20 from 06/05/2020). We studied 28 paired samples obtained upon admission of patients to the hospital and after 5–7 days of hospital stay. Paired sera of patients with COVID-19 were tested for antibodies to influenza A and B viruses. The presence of IgG antibodies specific to the SARS-CoV-2 spike (S) protein was studied using an enzyme-linked immunosorbent assay (ELISA). The serum concentration of C-reactive protein and the neutrophil-lymphocyte ratio on the day of hospitalization were also assessed.</p> <p><bold><italic>RESULTS:</italic></bold> At least a 4-fold increase in serum IgG antibodies to SARS-CoV-2 S protein was found both in patients with PCR-confirmed SARS-CoV-2 infection and without PCR confirmation. It was shown that out of 18 patients with moderate and severe forms of COVID-19 infection, six of them showed at least a 4-fold increase in antibodies to influenza A/H1N1, in one to influenza A/H3N2 and in two cases to the influenza B. Laboratory data in these two groups were characterized by significant increases in serum C-reactive protein and neutrophil-lymphocyte ratio concentrations compared with the moderate COVID-19 group.</p> <p><bold><italic>CONCLUSIONS:</italic></bold> Serological diagnostics can additionally detect cases of coronavirus infection when the virus was not detected by PCR. In moderate and severe cases of COVID-19, coinfections with influenza A and B viruses have been identified. The results obtained confirm the need for anti-influenza immunization during the SARS-CoV-2 pandemic. Influenza virus screening can significantly improve patient management because recommended antiviral drugs (neuraminidase inhibitors) are available.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование.</italic></bold> Несмотря на глобальное распространение новой коронавирусной инфекции (COVID-19), вызванной вирусом SARS-CoV-2, механизмы патогенеза тяжелых инфекций остаются недостаточно изученными. Не выяснена также роль коморбидности с другими сезонными вирусными инфекциями, включая грипп, в патогенезе тяжелого течения COVID-19.</p> <p><bold><italic>Материалы и методы.</italic></bold> В настоящем исследовании использованы сыворотки крови, оставшиеся после текущих лабораторных исследований пациентов с разной степенью тяжести COVID-19. Изучено 28 парных проб, полученных при поступлении пациентов в стационар и через 5–7 дней пребывания в стационаре. Парные сыворотки пациентов с COVID-19 были протестированы на антитела к вирусам гриппа А и В. Наличие антител IgG, специфичных к спайковому (S) белку SARS-CoV-2, изучали с помощью иммуноферментного анализа. Оценивали также сывороточную концентрацию С-реактивного белка и нейтрофильно-лимфоцитарное отношение в день госпитализации.</p> <p><bold><italic>Результаты.</italic></bold> По крайней мере 4-кратное увеличение уровня сывороточных антител IgG к S-белку SARS-CoV-2 обнаружено как у пациентов с подтвержденной полимеразной цепной реакцией COVID-19, так и без подтверждения. Из 18 пациентов со средней и тяжелой формами COVID-19 в шести случаях выявлено как минимум 4-кратное повышение уровня антител к гриппу A/H1N1, в одном — к гриппу A/H3N2 и в двух — к вирусу гриппа В. Лабораторные показатели в этих двух группах характеризовались значительным увеличением сывороточной концентрации С-реактивного белка и нейтрофильно-лимфоцитарного отношения по сравнению с группой пациентов с умеренной степенью тяжести COVID-19.</p> <p><bold><italic>Заключение.</italic></bold> С помощью серологической диагностики можно дополнительно выявлять случаи коронавирусной инфекции, когда вирус не обнаружен методом полимеразной цепной реакции. При среднетяжелых и тяжелых случаях COVID-19 обнаружены случаи коинфицирования с вирусами гриппа А и В. Результаты подтверждают необходимость противогриппозной иммунизации в период пандемии COVID-19. Скрининг на вирус гриппа может значительно улучшить тактику лечения пациента, поскольку существуют рекомендованные противовирусные препараты (ингибиторы нейраминидазы).</p></trans-abstract><kwd-group xml:lang="en"><kwd>coronavirus infection</kwd><kwd>influenza viruses</kwd><kwd>serodiagnostics</kwd><kwd>coinfection</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>коронавирусная инфекция</kwd><kwd>вирусы гриппа</kwd><kwd>серодиагностика</kwd><kwd>коинфекция</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено при финансовой поддержке бюджетных средств ФГБНУ «Институт экспериментальной медицины» в рамках проекта № 2018-557-003 по теме государственного задания «Молекулярно-генетические и клеточные основы патогенеза, диагностики и лечения социально значимых заболеваний инфекционной и неинфекционной природы». Исследование частично поддержано Правительством Санкт-Петербурга в сфере научной и научно-технической деятельности за 2020 г. (грант № 335-20).</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. DOI: 10.1038/s41579-020-00459-7</mixed-citation><mixed-citation xml:lang="ru">Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19 // Nat. Rev. Microbiol. 2021. Vol. 19, No. 3. P. 141–154. DOI: 10.1038/s41579-020-00459-7</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Wu X, Cai Y, Huang X, et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China. Emerg Infect Dis. 2020;26(6):1324–1326. DOI: 10.3201/eid2606.200299</mixed-citation><mixed-citation xml:lang="ru">Wu X., Cai Y., Huang X. et al. Co-infection with SARS-CoV-2 and influenza A virus in patient with pneumonia, China // Emerg. Infect. Dis. 2020. Vol. 26, No. 6. P. 1324–1326. DOI: 10.3201/eid2606.200299</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Cuadrado-Payán E, Montagud-Marrahi E, Torres-Elorza M, et al. SARS-CoV-2 and influenza virus co-infection. Lancet. 2020;395(10236):e84. DOI: 10.1016/S0140-6736(20)31052-7</mixed-citation><mixed-citation xml:lang="ru">Cuadrado-Payán E., Montagud-Marrahi E., Torres-Elorza M. et al. SARS-CoV-2 and influenza virus co-infection // Lancet. 2020. Vol. 395, No. 10236. P. e84. DOI: 10.1016/S0140-6736(20)31052-7</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250–256. DOI: 10.1002/jmv.26232</mixed-citation><mixed-citation xml:lang="ru">Hu B., Huang S., Yin L. The cytokine storm and COVID-19 // J. Med. Virol. 2021. Vol. 93, No. 1. P. 250–256. DOI: 10.1002/jmv.26232</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Int Med. 2020;180(7):934–943. DOI: 10.1001/jamainternmed.2020.0994</mixed-citation><mixed-citation xml:lang="ru">Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China // JAMA Int. Med. 2020. Vol. 180, No. 7. P. 934–943. DOI: 10.1001/jamainternmed.2020.0994</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol. 1999;37(4):937–943. DOI: 10.1128/JCM.37.4.937-943.1999</mixed-citation><mixed-citation xml:lang="ru">Rowe T., Abernathy R.A., Hu-Primmer J. et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays // J. Clin. Microbiol. 1999. Vol. 37, No. 4. P. 937–943. DOI: 10.1128/JCM.37.4.937-943.1999</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak. J Med Virol. 2020;92(11):2870–2873. DOI: 10.1002/jmv.26163.</mixed-citation><mixed-citation xml:lang="ru">Yue H., Zhang M., Xing L. et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak // J. Med. Virol. 2020. Vol. 92, No. 11. P. 2870–2873. DOI: 10.1002/jmv.26163</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Bai L, Zhao Y, Dong J, et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity. Cell Res. 2021;31(4):395–403. DOI: 10.1038/s41422-021-00473-1</mixed-citation><mixed-citation xml:lang="ru">Bai L., Zhao Y., Dong J. et al. Coinfection with influenza A virus enhances SARS-CoV-2 infectivity // Cell. Res. 2021. Vol. 31, No. 4. P. 395–403. DOI: 10.1038/s41422-021-00473-1</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Stringer D, Braude P, Myint PK, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420–429. DOI: 10.1093/ije/dyab012</mixed-citation><mixed-citation xml:lang="ru">Stringer D., Braude P., Myint P.K. et al. The role of C-reactive protein as a prognostic marker in COVID-19 // Int. J. Epidemiol. 2021. Vol. 50, No. 2. P. 420–429. DOI: 10.1093/ije/dyab012</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Kulkarni A, Divya Prabhu, Likitesh AB, et al. Utility of neutrophil-lymphocyte ratio (NLR) as an indicator of disease severity and prognostic marker among patients with COVID-19 infection in a tertiary care centre in Bangalore – a retrospective study. Journal of Evidence Based Medicine and Healthcare. 2021;8(16):1020–1024. DOI: 10.18410/jebmh/2021/197</mixed-citation><mixed-citation xml:lang="ru">Kulkarni A., Divya Prabhu, Likitesh A.B. et al. Utility of neutrophil-lymphocyte ratio (NLR) as an indicator of disease severity and prognostic marker among patients with COVID-19 infection in a tertiary care center in Bangalore – a retrospective study // Journal of Evidence Based Medicine and Healthcare. 2021. Vol. 8, No. 16. P. 1020–1024. DOI: 10.18410/jebmh/2021/197</mixed-citation></citation-alternatives></ref></ref-list></back></article>
